MEDP — Medpace Holdings, Inc.

Medpace (MEDP) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $659.9 million, a year-over-year increase of 23.7%. Year-to-date revenue reached $1.82 billion, up 15.9%.
• Net Income: $111.1 million, a 15.3% increase from $96.4 million in Q3 2024. Earnings per diluted share were $3.86 compared to $3.01 in the prior year.
• EBITDA: $148.4 million, up 24.9% year-over-year; EBITDA margin was 22.5% (22.3% in Q3 2024).
• Cash Flow: Generated $246.2 million from operating activities; net days sales outstanding was negative 64.3 days.
• Share Repurchase: Approximately 14,649 shares repurchased for $4.5 million in Q3; year-to-date repurchases totaled 2.96 million shares for $912.9 million.

2. Strategic Updates and Business Highlights

• Bookings: Record net bookings of $789.6 million, with a net book-to-bill ratio of 1.20, indicating strong demand.
• Backlog: Ending backlog as of September 30, 2025, was approximately $3 billion, up 2.5% year-over-year. About $1.84 billion of backlog is expected to convert to revenue in the next 12 months.
• Pipeline Growth: The total dollar value of awarded work not yet recognized in the backlog increased by approximately 30% year-over-year.
• Market Dynamics: The company noted that cancellations were well-managed, allowing for a strong performance despite previous concerns about funding and project delays.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Expected to be in the range of $2.48 billion to $2.53 billion, representing growth of 17.6% to 20% over 2024.
• EBITDA Guidance: Projected between $545 million and $555 million, indicating growth of 13.5% to 15.6% compared to 2024.
• 2026 Preliminary Outlook: Anticipated low double-digit revenue growth and high single-digit EBITDA growth. Pass-through costs are expected to remain high, constituting 41% to 42% of revenue.

4. Bad News, Challenges, or Points of Concern

• Pass-Through Costs: High levels of pass-through costs are expected to persist, impacting margins and overall profitability.
• Competitive Pressures: Increased competition from larger CROs entering the market could affect win rates, although the company maintains a strong competitive position.
• Cancellations: While cancellations were well-managed in Q3, they remain a significant risk factor that could impact future performance.
• Hiring Needs: The company anticipates needing to accelerate headcount growth to support increased business activity, particularly in North America and Asia Pacific.

5. Notable Q&A Insights

• Cancellations vs. Business Environment: CEO August Troendle emphasized that cancellations were the primary driver of recent challenges rather than a weak business environment.
• Burn Rate Dynamics: The burn rate is expected to stabilize as new studies ramp up, with a potential leveling off in pass-through costs.
• Therapeutic Mix: The company noted that metabolic studies, particularly GLP-1, are a significant driver of growth, comprising a large portion of awarded work.
• Pre-Backlog Insights: The pre-backlog of awarded studies is larger than the current backlog and is expected to contribute positively to revenue generation as projects progress.

This summary encapsulates the key financial metrics, strategic updates, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Medpace's performance and outlook for Q3 2025.